Bayer’s Dual Catalysts: A Chinese Drug Filing and a Pivotal August Calendar Converge
Published on 07/30/2026 at 21:02 | Redaktion boerse-global.de
Bayer is entering a defining stretch of the year, with two significant events unfolding in quick succession that could reshape both its pharmaceutical pipeline and its legal landscape. The German life-sciences group has submitted a regulatory application in China to expand the use of its kidney drug Kerendia, while simultaneously preparing for a critical court hearing next month tied to its multibillion-dollar glyphosate settlement. Investors, meanwhile, are digesting a second-quarter earnings report due next Tuesday that will test whether the momentum from a stellar first quarter can be sustained.
Shares rose 1.77 percent to €48.30 on Thursday, extending a weekly gain that now stands at 4.64 percent. The stock has climbed 30.51 percent since the start of the year, though it remains roughly 10 percent below its 52-week high of €53.86 reached on July 3. The 200-day moving average sits at €39.09, well below the current price, underscoring the scale of the recent rally.
China Filing Targets a Vast, Underserved Patient Pool
Bayer’s application to China’s National Medical Products Administration seeks approval for finerenone — marketed as Kerendia and Firialta — to treat adults with chronic kidney disease not caused by diabetes. The drug is already approved in more than 100 countries, but only for patients with kidney disease linked to type 2 diabetes and for certain forms of heart failure. The expanded indication would open up a dramatically larger market.
The submission is backed by the FIND-CKD phase 3 trial, the largest study to date focused on non-diabetic chronic kidney disease. Results presented at the ERA Congress 2026 and published in the New England Journal of Medicine showed that finerenone significantly slowed disease progression and reduced cardiovascular and renal events compared with placebo. This marks the fifth completed phase 3 trial to deliver positive results for the molecule.
Should investors sell immediately? Or is it worth buying Bayer?
The commercial opportunity is substantial. An estimated 850 million people worldwide live with chronic kidney disease, and more than half of cases are not diabetes-related. Bayer notes that patients with advanced non-diabetic kidney disease face a 2.6-times higher risk of kidney failure and cardiovascular events than the general population. A decision from Chinese regulators is expected in the coming months.
The Glyphosate Hearing and Legal Calendar
Just days after the earnings release, Bayer faces a pivotal moment in its long-running glyphosate litigation. On August 19, a U.S. court will hold a final hearing to approve the company’s proposed $7.25 billion class-action settlement designed to cap future claims. The hearing comes as Bayer’s Monsanto subsidiary recently withdrew its petition for anti-dumping tariffs on Chinese glyphosate imports, a move that removes one layer of trade friction from the legal tangle.
UBS, which rates Bayer a “Buy” with a €52 price target, has explicitly flagged the glyphosate hearing as both a risk and an opportunity for the stock. The range of analyst views remains wide: JPMorgan reiterated “Overweight” at €50 in mid-July, Barclays raised its target to €60, while Jefferies remains cautious with a “Hold” rating and €46 target, citing the company’s net debt burden.
Earnings Expectations and Operational Headwinds
The second-quarter and first-half 2026 report, due Tuesday, will be closely watched for signs that the strong first-quarter performance can be repeated. In Q1, Bayer posted earnings per share of €2.81, more than double the €1.32 recorded a year earlier, on quarterly revenue of €13.41 billion. The full-year analyst consensus stands at €4.38 per share.
However, headwinds are building. Since July 15, Germany has increased the mandatory manufacturer rebate on patented drugs from 7 percent to 15.5 percent, a policy change that will weigh on pharmaceutical margins in the coming quarters. Bayer is also pressing ahead with its restructuring: a new operating company is being created at the Bergkamen site to spin out infrastructure and site services, with full implementation planned for 2027.
Bayer at a turning point? This analysis reveals what investors need to know now.
On the financing front, Bayer placed $5 billion in new U.S. dollar bonds through its Bayer US Finance LLC subsidiary in July, fully guaranteed by the parent company. The issuance bolsters liquidity as the group continues to manage its balance sheet through the restructuring phase.
For investors, the next few weeks bundle together a quarterly earnings snapshot, a make-or-break legal hearing, and a steady stream of pipeline progress. The stock’s recent advance suggests the market is pricing in cautious optimism — but the outcomes of both the earnings report and the August 19 hearing will determine whether that optimism is justified.
Ad
Bayer Stock: New Analysis - 30 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
